Low-dose radiation before CAR-T for large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding low-dose total body radiation before standard CAR-T cell therapy (Kymriah) helps people with relapsed or refractory large B-cell lymphoma. It aims to improve the effectiveness of the CAR-T cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be eligible for standard CAR-T cell therapy (Tisa-cel, also known as Kymriah).
- You must be 18 years or older.
- Your large B-cell lymphoma must have come back or not responded after at least 2 prior treatments, and your tumor must have the CD19 protein.
- You must have at least one measurable tumor (by scan) before starting the low-dose total body radiation.
- Your heart, lungs, kidneys, and blood counts need to be good enough for the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether giving targeted radiation first can improve outcomes when you later receive CAR T-cell therapy for large B-cell lymphoma that has come back or is not responding to treatment. It may help shrink or control lymphoma spots before CAR T is infused.
This trial tests whether adding a targeted antibody (rituximab) before CAR T cell therapy improves outcomes for patients with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments.
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
This trial tests whether a low dose of total body radiation combined with CAR T-cell therapy can help people with certain types of lymphoma or multiple myeloma that have come back or stopped responding to other treatments. It may be an option for patients whose cancer is hard to treat with standard therapies.
Hear when a new Recurrent Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.